Erythropoietin after a century of research: younger than ever
- PMID:17253966
- DOI: 10.1111/j.1600-0609.2007.00818.x
Erythropoietin after a century of research: younger than ever
Abstract
In the light of the enthusiasm regarding the use of recombinant human erythropoietin (Epo) and its analogues for treatment of the anaemias of chronic renal failure and malignancies it is worth remembering that today's success has been based on a century of laborious research. The concept of the humoral regulation of haematopoiesis was first formulated in 1906. The term 'erythropoietin' for the erythropoiesis-stimulating hormone was introduced in 1948. Native human Epo was isolated in 1977 and its gene cloned in 1985. During the last 15 yr, major progress has been made in identifying the molecules controlling Epo gene expression, primarily the hypoxia-inducible transcription factors (HIF) that are regulated by specific O2 and oxoglutarate requiring Fe2+-containing dioxygenases. With respect to the action of Epo, its dimeric receptor (Epo-R) has been characterised and shown to signal through protein kinases, anti-apoptotic proteins and transcription factors. The demonstration of Epo-R in non-haematopoietic tissues indicates that Epo is a pleiotropic viability and growth factor. The neuroprotective and cardioprotective potentials of Epo are reviewed with a focus on clinical research. In addition, studies utilising the Epo derivatives with prolonged half-life, peptidic and non-peptidic Epo mimetics, orally active drugs stimulating endogenous Epo production and Epo gene transfer are reviewed.
Comment in
- Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.Huang J, Tefferi A.Huang J, et al.Eur J Haematol. 2009 Aug;83(2):154-5. doi: 10.1111/j.1600-0609.2009.01266.x. Epub 2009 Apr 10.Eur J Haematol. 2009.PMID:19366369No abstract available.
Similar articles
- Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression.Stockmann C, Fandrey J.Stockmann C, et al.Clin Exp Pharmacol Physiol. 2006 Oct;33(10):968-79. doi: 10.1111/j.1440-1681.2006.04474.x.Clin Exp Pharmacol Physiol. 2006.PMID:17002676Review.
- Molecular biology of erythropoietin.Jelkmann W.Jelkmann W.Intern Med. 2004 Aug;43(8):649-59. doi: 10.2169/internalmedicine.43.649.Intern Med. 2004.PMID:15468961Review.
- Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.Tanaka T, Nangaku M.Tanaka T, et al.Exp Cell Res. 2012 May 15;318(9):1068-73. doi: 10.1016/j.yexcr.2012.02.035. Epub 2012 Mar 6.Exp Cell Res. 2012.PMID:22414872
- Erythropoietin: physiology and pharmacology update.Fisher JW.Fisher JW.Exp Biol Med (Maywood). 2003 Jan;228(1):1-14. doi: 10.1177/153537020322800101.Exp Biol Med (Maywood). 2003.PMID:12524467Review.
- Erythropoietin, erythropoiesis and beyond.Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M.Chateauvieux S, et al.Biochem Pharmacol. 2011 Nov 15;82(10):1291-303. doi: 10.1016/j.bcp.2011.06.045. Epub 2011 Jul 7.Biochem Pharmacol. 2011.PMID:21782802Review.
Cited by
- Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases.Rey F, Balsari A, Giallongo T, Ottolenghi S, Di Giulio AM, Samaja M, Carelli S.Rey F, et al.ASN Neuro. 2019 Jan-Dec;11:1759091419871420. doi: 10.1177/1759091419871420.ASN Neuro. 2019.PMID:31450955Free PMC article.Review.
- Skeletal muscle intrinsic functional properties are preserved in a model of erythropoietin deficient mice exposed to hypoxia.Hagström L, Canon F, Agbulut O, Marchant D, Serrurier B, Richalet JP, Beaudry M, Bigard X, Launay T.Hagström L, et al.Pflugers Arch. 2010 Apr;459(5):713-23. doi: 10.1007/s00424-009-0775-7. Epub 2010 Jan 30.Pflugers Arch. 2010.PMID:20119684
- Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice.Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, Yamamoto M.Pan X, et al.PLoS One. 2011;6(10):e25839. doi: 10.1371/journal.pone.0025839. Epub 2011 Oct 11.PLoS One. 2011.PMID:22022454Free PMC article.
- Role of erythropoietin in the treatment of Alzheimer's disease: the story so far.Kalluru PKR, Bhavanthi S, Vashist S, Gopavaram RR, Mamilla M, Sharma S, Gundoji CR, Goguri SR.Kalluru PKR, et al.Ann Med Surg (Lond). 2024 May 1;86(6):3608-3614. doi: 10.1097/MS9.0000000000002113. eCollection 2024 Jun.Ann Med Surg (Lond). 2024.PMID:38846819Free PMC article.Review.
- The effects of topical erythropoietin on non-surgical treatment of periodontitis: a preliminary study.Aslroosta H, Yaghobee S, Akbari S, Kanounisabet N.Aslroosta H, et al.BMC Oral Health. 2021 May 6;21(1):240. doi: 10.1186/s12903-021-01607-y.BMC Oral Health. 2021.PMID:33957902Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials